 LEXINGTON, Mass.--BUSINESS WIRE--Aldeyra Therapeutics, Inc. Nasdaq: ALDX Aldeyra, a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Aldeyra also expects to grant the underwriters a 30-day option to purchase up to an addit 